Correlation Engine 2.0
Clear Search sequence regions

  • BGT1 (12)
  • cricetulus (1)
  • focal seizures (1)
  • GABA (6)
  • GAT1 (2)
  • humans (1)
  • methyl (1)
  • mice (2)
  • patients (1)
  • plasma membrane (2)
  • reflex (1)
  • seizures (1)
  • Slc6a12 (1)
  • transport proteins (2)
  • Sizes of these terms reflect their relevance to your search.

    Focal epileptic seizures can in some patients be managed by inhibiting γ-aminobutyric acid (GABA) uptake via the GABA transporter 1 (GAT1) using tiagabine (Gabitril®). Synergistic anti-seizure effects achieved by inhibition of both GAT1 and the betaine/GABA transporter (BGT1) by tiagabine and EF1502, compared to tiagabine alone, suggest BGT1 as a target in epilepsy. Yet, selective BGT1 inhibitors are needed for validation of this hypothesis. In that search, a series of BGT1 inhibitors typified by (1R,2S)-2-((4,4-bis(3-methylthiophen-2-yl)but-3-en-yl)(methyl)amino)cyclohexanecarboxylic acid (SBV2-114) was developed. A thorough pharmacological characterization of SBV2-114 using a cell-based [3H]GABA uptake assay at heterologously expressed BGT1, revealed an elusive biphasic inhibition profile with two IC50 values (4.7 and 556 μM). The biphasic profile was common for this structural class of compounds, including EF1502, and was confirmed in the MDCK II cell line endogenously expressing BGT1. The possibility of two binding sites for SBV2-114 at BGT1 was assessed by computational docking studies and examined by mutational studies. These investigations confirmed that the conserved residue Q299 in BGT1 is involved in, but not solely responsible for the biphasic inhibition profile of SBV2-114. Animal studies revealed anti-seizure effects of SBV2-114 in two mouse models, supporting a function of BGT1 in epilepsy. However, as SBV2-114 is apparent to be rather non-selective for BGT1, the translational relevance of this observation is unknown. Nevertheless, SBV2-114 constitutes a valuable tool compound to study the molecular mechanism of an emerging biphasic profile of BGT1-mediated GABA transport and the putative involvement of two binding sites for this class of compounds.


    Maria E K Lie, Stefanie Kickinger, Jonas Skovgaard-Petersen, Gerhard F Ecker, Rasmus P Clausen, Arne Schousboe, H Steve White, Petrine Wellendorph. Pharmacological Characterization of a Betaine/GABA Transporter 1 (BGT1) Inhibitor Displaying an Unusual Biphasic Inhibition Profile and Anti-seizure Effects. Neurochemical research. 2020 Jul;45(7):1551-1565

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32248400

    View Full Text